



Short version of press release from Emotra AB (publ)
Gothenburg October 31, 2013

Emotra signs agreement with clinical center in Ravensburg, Germany

Emotra has signed an agreement with “The Department of Psychiatry”, University of Ulm, in Ravensburg, Germany.

The institute, led by Professor Wolfgang Kaschka, is one of leading research institutions in the country and in the world, within the field of suicide prevention and electrodermal reactivity. Professor Kaschka is one of the coauthors of the scientific article, which was published in “Journal of Psychiatric Research”, from the follow up on 783 German patients, in cooperation between German research groups and Lars-Håkan Thorell, the inventor of EDOR.

The agreement is the third contract, which has been signed with clinical centers that will participate in the clinical evaluation of EDOR. In all, 15 leading European clinical teams should evaluate the use of EDOR, during the next two years. Discussions and negotiations are ongoing with several other groups from different countries. For the purpose of preparing these clinical studies, applications to ethical committees and preparations of CE-marking are ongoing parallel to this other work.

Emotra is at present in a very dynamic phase and its activities involve an increasing number of clinical centers. In order to minimize the financial risks, all work is done in a small organization and in such a cost effective manner as possible. When the support for EDOR from these clinical teams, is strong enough, the method will be launched in Europe.

For more information, please contact

Claes Holmberg, President and CEO, Emotra AB, Telephone: +46708254547, claes@emotra.se

or Lars-Håkan Thorell, Research Manager, Emotra AB, Telephone: +46703263853, lars@emotra.se

Emotra AB is a Swedish medical device company focusing on research, development, clinical trials and marketing within the field of suicide prevention. The company's method, EDOR, is an objective and quantitative diagnostic psychophysiological test of hyporeactivity. During the test, the patients listen and react to a series of sound signals. The response is measured as minimal fluctuations in the dermal electrical conductivity and analyzed. With research and clinical documentation an extremely sensitive and accurate test, with the purpose of evaluating suicide risk, has been developed.

Emotra AB (publ), Göteborgsvägen 74, 433 63 Sävedalen, Sweden

Telephone: +46 708 25 45 47, www.emotra.se